 |
|
|
|
Ambler class |
Protein name |
PDB code |
Resolution (Å) |
Release date |
UniProt code |
PubMed ID |
DOI |
PDB |
Mutations |
Ligands |
Space group |
Unit cell parameters |
Z value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ||||||||
| C | ACC-1 | 6K8X | 1.59 | 2019-10-16 | Q9XB24 | 31451494 | 10.1128/AAC.01411-19 | pdb | C 1 2 1 | 133.160 60.290 56.215 ♦ 90.00 111.99 90.00 | 4 | ||
| C | ACC-1 | 6K9T | 1.46 | 2019-10-16 | Q9XB24 | 31451494 | 10.1128/AAC.01411-19 | pdb | *CEF | C 1 2 1 | 133.219 60.416 56.039 ♦ 90.00 111.98 90.00 | 4 | |
| C | ACC-1 | 6KA5 | 1.59 | 2019-10-16 | Q9XB24 | 31451494 | 10.1128/AAC.01411-19 | pdb | *1S7 | C 1 2 1 | 133.092 60.340 56.490 ♦ 90.00 111.93 90.00 | 4 | |
| C | ACC-1 | 6KBY | 1.10 | 2019-10-16 | Q9XB24 | 31451494 | 10.1128/AAC.01411-19 | pdb | AMP | C 1 2 1 | 132.270 60.230 56.140 ♦ 90.00 112.04 90.00 | 4 | |
| C | ACC-1 | 6M5H | 1.20 | 2021-01-20 | Q9XB24 | 32888908 | 10.1016/J.ABB.2020.108570 | pdb | Y149F | C 1 2 1 | 130.150 59.980 55.100 ♦ 90.00 111.31 90.00 | 4 | |
| C | ACC-1 | 6M5P | 1.25 | 2021-01-20 | Q9XB24 | 32888908 | 10.1016/J.ABB.2020.108570 | pdb | Y149F | *MER | C 1 2 1 | 129.918 60.233 54.518 ♦ 90.00 110.71 90.00 | 4 |
| C | ACC-1 | 6M5Q | 1.30 | 2021-01-20 | Q9XB24 | 32888908 | 10.1016/J.ABB.2020.108570 | pdb | Y149F | *IM2 | C 1 2 1 | 129.918 60.233 54.518 ♦ 90.00 110.71 90.00 | 4 |
Statistics (number of structures): Overall (1663); class A (626); subclass B1 (403); subclass B2 (16); subclass B3 (104); class C (246); class D (268).
Last updated: November 20, 2024.
If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.
The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).
Contact: contact@bldb.eu